Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms

Blood

Volumn 123, Issue 17, 2014, Pages 2645-2651

  Wang, Sa A ^a   Hasserjian, Robert P ^b   Fox, Patricia S ^a   Rogers, Heesun J ^c   Geyer, Julia T ^d   Chabot Richards, Devon ^e   Weinzierl, Elizabeth ^f   Hatem, Joseph ^g   Jaso, Jesse ^a   Kanagal Shamanna, Rashmi ^a   Stingo, Francesco C ^a   Patel, Keyur P ^a   Mehrotra, Meenakshi ^a   Bueso Ramos, Carlos ^a   Young, Ken H ^a   Dinardo, Courtney D ^a   Verstovsek, Srdan ^a   Tiu, Ramon V ^c   Bagg, Adam ^g   Hsi, Eric D ^c   Arber, Daniel A ^f   Foucar, Kathryn ^e   Luthra, Raja ^a   Orazi, Attilio ^d   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; LACTATE DEHYDROGENASE;

AGED; ARTICLE; ATYPICAL CHRONIC MYELOID LEUKEMIA; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CYTOGENETICS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MYELOBLAST; MYELODYSPLASTIC SYNDROME; MYELOID PROGENITOR CELL; MYELOPROLIFERATIVE NEOPLASM; ONCOGENE RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; SOMATIC MUTATION; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE PRECURSOR CELLS; HEMATOLOGIC NEOPLASMS; HUMANS; KARYOTYPING; L-LACTATE DEHYDROGENASE; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; LEUKOCYTOSIS; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; MYELODYSPLASTIC-MYELOPROLIFERATIVE DISEASES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 84899652823     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-02-553800     Document Type: Article

References (36)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5): 937-951.
2. Jaffe ES, Stein NL, Stein H, Vardiman JH. The World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
3. Galton DA. Haematological differences between chronic granulocytic leukaemia, atypical chronic myeloid leukaemia, and chronic myelomonocytic leukaemia. Leuk Lymphoma. 1992;7(5-6): 343-350.
4. Bennett JM, Catovsky D, Daniel MT, et al; Proposals by the French-American-British Cooperative Leukaemia Group. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Br J Haematol. 1994;87(4): 746-754.
5. Breccia M, Biondo F, Latagliata R, Carmosino I, Mandelli F, Alimena G. Identification of risk factors in atypical chronic myeloid leukemia. Haematologica. 2006;91(11): 1566-1568.
6. Broséus J, Alpermann T, Wulfert M, et al; MPN and MPNr-EuroNet (COST Action BM0902). Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia. 2013;27(9): 1826-1831.
7. Cannella L, Breccia M, Latagliata R, Frustaci A, Alimena G. Clinical and prognostic features of patients with myelodysplastic/myeloproliferative syndrome categorized as unclassified (MDS/MPD-U) by WHO classification. Leuk Res. 2008; 32(3): 514-516.
8. Vardiman JWBJ, Bain BJ, Brunning RD, Thiele J. Atypical chronic myeloid leukaemia, BCR-ABL1 negative. In: Swerdlow SHCE, Lee Harris N, et al, eds. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008: 80-81.
9. Jeromin S, Haferlach T, Grossmann V, et al. High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms. Haematologica. 2013;98(2):e15-e17.
10. Wang SA, Hasserjian RP, Loew JM, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features. Leukemia. 2006;20(9): 1641-1644.
11. Dinardo CD, Daver N, Jain N, et al. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy [published online ahead of print January 10, 2014]. Leukemia. 2014.
12. Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368(19): 1781-1790.
13. Pardanani A, Lasho TL, Laborde RR, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia. 2013;27(9): 1870-1873.
14. Fleischman AG, Maxson JE, Luty SB, et al. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood. 2013;122(22): 3628-3631.
15. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25): 2379-2390.
16. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369(25): 2391-2405.
17. Lasho TL, Elliott MA, Pardanani A, Tefferi A. CALR mutation studies in chronic neutrophilic leukemia[published online ahead of print January 13, 2014]. Am J Hematol. 2014.
18. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood. 2006;107(5): 1747-1750.
19. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8): 1128-1132.
20. Contal C, O'Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal. 1999;30(3): 253-270.
21. Such E, Germing U, Malcovati L, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121(15): 3005-3015.
22. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6): 2079-2088.
23. Wang SA, Galili N, Cerny J, et al. Chronic myelomonocytic leukemia evolving from preexisting myelodysplasia shares many features with de novo disease. Am J Clin Pathol. 2006; 126(5): 789-797.
24. Fu B, Jaso JM, Sargent RL, et al. Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems [published online ahead of print November 1, 2013]. Mod Pathol. 2013.
25. Della Porta MG, Malcovati L, Boveri E, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009; 27(5): 754-762.
26. Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms [published online ahead of print January 20, 2014]. Leukemia. 2014.
27. Geyer JT, Verma S, Mathew S, et al. Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q). Hum Pathol. 2013;44(3): 346-356.
28. Patnaik MM, Lasho TL, Finke CM, et al. WHOdefined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia. 2010; 24(7): 1283-1289.
29. Invernizzi R, Custodi P, de Fazio P, et al. The syndrome of abnormal chromatin clumping in leucocytes: clinical and biological study of a case. Haematologica. 1990;75(6): 532-536.
30. Fend F, Horn T, Koch I, Vela T, Orazi A. Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm. Leuk Res. 2008;32(12): 1931-1935.
31. Kosmider O, Itzykson R, Chesnais V, et al. Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia. Leukemia. 2013;27(9): 1946-1949.
32. Meggendorfer M, Bacher U, Alpermann T, et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i (17)(q10), ASXL1 and CBL mutations. Leukemia. 2013;27(9): 1852-1860.
33. Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31(19): 2428-2436.
34. Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood. 2012; 120(15): 3080-3088.
35. Piazza R, Valletta S, Winkelmann N, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet. 2013;45(1): 18-24.
36. Orazi A, Germing U. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia. 2008;22(7): 1308-1319.